Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Peptic Ulcer

Free Subscription Articles published in J Gastroenterol Hepatol Retrieve available abstracts of 106 articles: HTML format

Single Articles

September 2026
1. NISA NU, Mughal A, Adnan S, Batool B, et al
   Comment on "Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials".
   J Gastroenterol Hepatol. 2026 Sep 21. doi: 10.1111/jgh.70734.
   PubMed    
   
   
   
2. RAO A, Ali SH, Awais M
   Comment on Letter to the Editor "Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis".
   J Gastroenterol Hepatol. 2026 Sep 8. doi: 10.1111/jgh.70726.
   PubMed    
   
   
   
3. JESWANI W, Jeswani AK
   Comment on: "Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials".
   J Gastroenterol Hepatol. 2026 Sep 4. doi: 10.1111/jgh.70725.
   PubMed    
   
   
   
4. QIU C
   Comment on "Preventive Effect of Helicobacter pylori Treatment on Colorectal Cancer Incidence and Mortality".
   J Gastroenterol Hepatol. 2026 Sep 4. doi: 10.1111/jgh.70737.
   PubMed    
   
   
   
5. MUHAMMAD YOUSUF Y
   Methodological Considerations Regarding the Meta-Analysis of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication.
   J Gastroenterol Hepatol. 2026 Sep 4. doi: 10.1111/jgh.70722.
   PubMed    
   
   
   
6. ALI A, Hussain MZ
   Letter to the Editor on: Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.
   J Gastroenterol Hepatol. 2026 Sep 3. doi: 10.1111/jgh.70728.
   PubMed    
   
   
   
7. AMIR F, Haider SUR, Gul F
   Methodological Considerations in Assessing the Link Between Helicobacter pylori Eradication and Colorectal Cancer.
   J Gastroenterol Hepatol. 2026 Sep 3. doi: 10.1111/jgh.70731.
   PubMed    
   
   
   
8. KUMARI A, Heerani G, Kumar V, Devi C, et al
   Response to "Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials".
   J Gastroenterol Hepatol. 2026 Sep 2. doi: 10.1111/jgh.70711.
   PubMed    
   
   
   August 2026
9. HAN S, Lee H, Kim S, Choi HY, et al
   Pharmacokinetic and Pharmacodynamic Characteristics of Tegoprazan According to Helicobacter pylori Infection Status.
   J Gastroenterol Hepatol. 2026 Aug 31. doi: 10.1111/jgh.70671.
   PubMed     Abstract available
   
   
   
10. SONG Y, Li Z, Zhang X, Fang S, et al
    ChatGPT-4o for Endoscopic Differentiation of Autoimmune Gastritis From Helicobacter pylori-Associated Atrophic Gastritis: A Post Hoc Head-to-Head Comparison With Specialized Deep Learning.
    J Gastroenterol Hepatol. 2026 Aug 24. doi: 10.1111/jgh.70694.
    PubMed    
    
    
    
11. GAO Y, Huang Y, Chen J, Qiu S, et al
    Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Randomized Controlled Trial.
    J Gastroenterol Hepatol. 2026 Aug 23. doi: 10.1111/jgh.70677.
    PubMed     Abstract available
    
    
    
12. XUE F, Zhao S, Han P
    Comment on "High-Dose Oral Omeprazole Versus Continuous Intravenous Pantoprazole in Patients With High-Risk Peptic Ulcer Bleeding".
    J Gastroenterol Hepatol. 2026 Aug 4. doi: 10.1111/jgh.70640.
    PubMed    
    
    
    July 2026
13. KHAN A, Khokhar ME, Kumari D, Dawani P, et al
    Is Duration the Only Variable? Methodological Considerations in Comparing 10- and 14-Day Vonoprazan-Based Helicobacter pylori Therapy.
    J Gastroenterol Hepatol. 2026 Jul 28. doi: 10.1111/jgh.70628.
    PubMed    
    
    
    
14. CHOWDHARY R, Prasad S, Koo TH, Liu BDX, et al
    Burden of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive US Healthcare Analysis.
    J Gastroenterol Hepatol. 2026 Jul 22. doi: 10.1111/jgh.70609.
    PubMed     Abstract available
    
    
    
15. SRIYUDTHSAK K, Nalinthassanai N, Sriapiraksa B, Rattanachaisit P, et al
    High-Dose Oral Omeprazole Versus Continuous Intravenous Pantoprazole in Patients With High-Risk Peptic Ulcer Bleeding: A Single-Blinded Multicenter RCT.
    J Gastroenterol Hepatol. 2026 Jul 12. doi: 10.1111/jgh.70566.
    PubMed     Abstract available
    
    
    
16. PASSOS PRC, Filho VOC, Noronha MM, Maia MCB, et al
    Eradication of Helicobacter pylori With Vonoprazan-Amoxicillin Dual Therapy as an Alternative for Bismuth-Based Quadruple Therapy: A Systematic Review and Noninferiority Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Jul 11. doi: 10.1111/jgh.70565.
    PubMed     Abstract available
    
    
    
17. FATIMA B
    Comment on "Association of Proton Pump Inhibitor and Potassium-Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5-Aminosalicylic Acid in Patients With Ulcerative Colitis".
    J Gastroenterol Hepatol. 2026 Jul 6. doi: 10.1111/jgh.70562.
    PubMed    
    
    
    
18. JUNG YS, Jeon S, Park B, Moon CM, et al
    Preventive Effect of Helicobacter pylori Treatment on Colorectal Cancer Incidence and Mortality.
    J Gastroenterol Hepatol. 2026 Jul 1. doi: 10.1111/jgh.70532.
    PubMed     Abstract available
    
    
    June 2026
19. ZHOU BG, Xu YM, Xu WJ, Liu J, et al
    Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.
    J Gastroenterol Hepatol. 2026 Jun 18. doi: 10.1111/jgh.70498.
    PubMed     Abstract available
    
    
    
20. SALMAN MS, Waqar S, Nisa NU, Umair S, et al
    Reporting Inconsistency and Interpretive Caution in a Multicenter Trial of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication.
    J Gastroenterol Hepatol. 2026 Jun 17. doi: 10.1111/jgh.70513.
    PubMed    
    
    
    
21. MAYORI F
    Comment on: Efficacy and Safety of Quadruple Therapy With Semisynthetic Tetracycline for Helicobacter pylori Eradication: A Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Jun 8. doi: 10.1111/jgh.70492.
    PubMed    
    
    
    
22. AFZAL S, Afzal N, Afzal S
    Brief Critique on "Efficacy and Safety of Quadruple Therapy With Semisynthetic Tetracycline for Helicobacter pylori Eradication": A Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Jun 5. doi: 10.1111/jgh.70491.
    PubMed    
    
    
    
23. ANAND T, Anand N
    The Importance of Strain-Specific Variability in Evaluating Helicobacter pylori and Barrett's Esophagus Association.
    J Gastroenterol Hepatol. 2026 Jun 5. doi: 10.1111/jgh.70484.
    PubMed    
    
    
    May 2026
24. KOUNTOURAS J, Kazakos E, Hourpouliadis I, Vardaka E, et al
    Helicobacter pylori and Porphyromonas gingivalis Infections as Potential Risk Predictors for Gastric Cancer and Two Types of Esophageal Cancer.
    J Gastroenterol Hepatol. 2026 May 31. doi: 10.1111/jgh.70464.
    PubMed    
    
    
    
25. YAR S, Ashfaq T, Nag IS, Ahlawat D, et al
    Mechanism, Association, and Actionable Evidence: Comment on Engin et al. on Helicobacter pylori and Extra-Gastric Cancer Risk.
    J Gastroenterol Hepatol. 2026 May 15. doi: 10.1111/jgh.70432.
    PubMed    
    
    
    
26. RIAZ A, Kaisrani A
    "Comment on: Efficacy and Safety of Semisynthetic Tetracycline Containing Quadruple Therapy for Helicobacter pylori Eradication".
    J Gastroenterol Hepatol. 2026 May 11. doi: 10.1111/jgh.70424.
    PubMed    
    
    
    
27. JIANG W
    Noninferiority of 14-THA for Helicobacter pylori Eradication: Reconsidering the Evidence.
    J Gastroenterol Hepatol. 2026 May 10. doi: 10.1111/jgh.70431.
    PubMed    
    
    
    April 2026
28. ENGIN ED, Engin AB, Engin A
    Immune Evasion of Helicobacter pylori and Extra-Gastric Cancer Risk.
    J Gastroenterol Hepatol. 2026 Apr 13. doi: 10.1111/jgh.70376.
    PubMed     Abstract available
    
    
    
29. ALSALEH T, Ferreira CN, Akram H, Jose C, et al
    Ten vs. 14 Days of Vonoprazan-Based Therapy for Helicobacter pylori: Systematic Review and Meta-Analysis of Randomized Trials.
    J Gastroenterol Hepatol. 2026 Apr 9. doi: 10.1111/jgh.70367.
    PubMed     Abstract available
    
    
    
30. KOUNTOURAS J, Polyzos SA, Kazakos E, Doulberis M, et al
    Helicobacter pylori Infection as a Potential Risk Factor for Barrett's Esophagus.
    J Gastroenterol Hepatol. 2026 Apr 8. doi: 10.1111/jgh.70389.
    PubMed    
    
    
    March 2026
31. LEELAKUSOLVONG S, Chua TS, Quach DT, Ong AM, et al
    Rationalizing Proton Pump Inhibitor Use: Southeast Asia Consensus Recommendations.
    J Gastroenterol Hepatol. 2026 Mar 26. doi: 10.1111/jgh.70350.
    PubMed     Abstract available
    
    
    
32. GUO QQ, Zhang J, Zhu XJ, Li WY, et al
    Efficacy and Safety of Quadruple Therapy With Semisynthetic Tetracycline for Helicobacter pylori Eradication: A Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Mar 19. doi: 10.1111/jgh.70348.
    PubMed     Abstract available
    
    
    
33. KOUNTOURAS J, Polyzos SA, Kazakos E, Lazaraki G, et al
    A Potential Impact of Helicobacter pylori Infection on Gastroesophageal Reflux Disease.
    J Gastroenterol Hepatol. 2026 Mar 10. doi: 10.1111/jgh.70327.
    PubMed    
    
    
    
34. TAN JT, Mao X, Cheung CL, Ooi PH, et al
    Effects of Successful Versus Delayed/Failed Helicobacter pylori Eradication Therapy on Subsequent Fracture Risk: a Population-Based Cohort Study.
    J Gastroenterol Hepatol. 2026 Mar 8. doi: 10.1111/jgh.70310.
    PubMed     Abstract available
    
    
    February 2026
35. NISHIDA H
    Comment on "Helicobacter pylori Screening and Eradication in Junior High School Students in Yokosuka, Japan: Prevalence, Eradication Rates, and Challenges" (J Gastroenterol Hepatol 2025; 40:2499-2506).
    J Gastroenterol Hepatol. 2026 Feb 6. doi: 10.1111/jgh.70284.
    PubMed    
    
    
    January 2026
36. SANTO P, Meine GC, Prado RMG, Pessorrusso F, et al
    Hemostatic Powder for Non-Malignant Upper Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Gastroenterol Hepatol. 2026 Jan 23. doi: 10.1111/jgh.70249.
    PubMed     Abstract available
    
    
    December 2025
37. OTANI K, Lai WY, Liou JM, Fujiwara Y, et al
    Antibiotic Resistance in Helicobacter pylori in the Asia-Pacific Region: A Call for Coordinated Regional Strategies.
    J Gastroenterol Hepatol. 2025 Dec 30. doi: 10.1111/jgh.70227.
    PubMed     Abstract available
    
    
    
38. ICHITA C, Kusano C, Gotoda T, Hagiwara Y, et al
    Prevalence and Incidence of Gastric Cancer Among Helicobacter pylori-Naive Individuals in Japan: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2025 Dec 29. doi: 10.1111/jgh.70217.
    PubMed     Abstract available
    
    
    
39. CHIANG TH, Chuang SL, Chu TC, Lee YC, et al
    Population-Based Helicobacter pylori Screening for Gastric Cancer Prevention: Opportunities and Challenges in Asia.
    J Gastroenterol Hepatol. 2025 Dec 22. doi: 10.1111/jgh.70209.
    PubMed     Abstract available
    
    
    
40. FAN Y, Li C, Zhang W, Shi J, et al
    Fourteen-and Ten-Day Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Eradication-A Noninferiority, Multicenter, Randomized Controlled Trial.
    J Gastroenterol Hepatol. 2025 Dec 10. doi: 10.1111/jgh.70180.
    PubMed     Abstract available
    
    
    
41. JANG Y, Park J, Kang D, Kim JH, et al
    Safety of Potassium-Competitive Acid Blockers Compared With Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease and Peptic Ulcer Disease: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2025 Dec 2. doi: 10.1111/jgh.70178.
    PubMed     Abstract available
    
    
    
42. CHENG Y, Ye Q, He M, Ma W, et al
    Randomized Comparison of Vonoprazan-Amoxicillin Dual Therapy Versus Bismuth Quadruple Therapies for Helicobacter pylori Eradication: A Multicenter Trial Evaluating National Centralized Drug Procurement Antibiotics.
    J Gastroenterol Hepatol. 2025 Dec 2. doi: 10.1111/jgh.70179.
    PubMed     Abstract available
    
    
    November 2025
43. LIU J, He C
    Comment on Helicobacter pylori Infection Associated With an Increased Incidence of Cholelithiasis: A Retrospective Real-World Cohort Study of 50 832 Patients.
    J Gastroenterol Hepatol. 2025 Nov 30. doi: 10.1111/jgh.70115.
    PubMed    
    
    
    
44. NG QX, Zhou KX, Siah KTH
    Protective or Perplexing? Rethinking the Helicobacter pylori-GERD Relationship.
    J Gastroenterol Hepatol. 2025 Nov 6. doi: 10.1111/jgh.70159.
    PubMed    
    
    
    October 2025
45. MAHESHWARI P
    Letter to the Editor Regarding "Asia-Pacific Survey on the Management of Helicobacter pylori Infection".
    J Gastroenterol Hepatol. 2025 Oct 2. doi: 10.1111/jgh.70092.
    PubMed    
    
    
    September 2025
46. OTANI K, Hang DV, Pittayanon R, Liu H, et al
    Response to the Letter by Dr. Parena Maheshwari Regarding Our Manuscript, "Asia-Pacific Survey on the Management of Helicobacter pylori Infection".
    J Gastroenterol Hepatol. 2025 Sep 25. doi: 10.1111/jgh.70087.
    PubMed     Abstract available
    
    
    
47. KOUNTOURAS J, Zavos C, Vardaka E, Kazakos E, et al
    Helicobacter pylori and Metabolic Syndrome-Related Mast Cells May Be Potential Risk Factors for the Increased Prevalence of Barrett's Esophagus.
    J Gastroenterol Hepatol. 2025 Sep 16. doi: 10.1111/jgh.70076.
    PubMed    
    
    
    
48. 
    Correction to "Vonoprazan is Superior to Lansoprazole for Healing of Severe but Not Mild Erosive Esophagitis: A Systematic Review With Meta-Analysis of Randomized Controlled Trials".
    J Gastroenterol Hepatol. 2025 Sep 5. doi: 10.1111/jgh.70063.
    PubMed    
    
    
    
49. SAITO Y, Saito H, Matsuda T, Nishikawa Y, et al
    Helicobacter pylori Screening and Eradication in Junior High School Students in Yokosuka, Japan: Prevalence, Eradication Rates, and Challenges.
    J Gastroenterol Hepatol. 2025 Sep 3. doi: 10.1111/jgh.70067.
    PubMed     Abstract available
    
    
    July 2025
50. KOH JH, Anna O, Teng JJR, R R, et al
    Over-the-Scope Clip Versus Standard Endoscopic Treatment in Patients With Acute Nonvariceal Upper Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2025 Jul 30. doi: 10.1111/jgh.70022.
    PubMed     Abstract available
    
    
    
51. DAI D, Quan X, Zheng Y, Wang Y, et al
    A Multisite Fusion-Based Deep Convolutional Neural Network for Classification of Helicobacter pylori Infection Status Using Endoscopic Images: A Multicenter Study.
    J Gastroenterol Hepatol. 2025 Jul 19. doi: 10.1111/jgh.70004.
    PubMed     Abstract available
    
    
    
52. WANG H, Qu Y, Lin Y, Liu Z, et al
    Helicobacter pylori Infection and Eradication in Relation to Gastroesophageal Reflux Disease.
    J Gastroenterol Hepatol. 2025 Jul 15. doi: 10.1111/jgh.70009.
    PubMed     Abstract available
    
    
    May 2025
53. SHIBATA H, Fujiyoshi T, Kawata N, Obayashi T, et al
    Vonoprazan or Proton Pump Inhibitor for Gastric Endoscopic Submucosal Dissection in Patients Taking Antithrombotic Agents.
    J Gastroenterol Hepatol. 2025 May 27. doi: 10.1111/jgh.17027.
    PubMed     Abstract available
    
    
    
54. JING W, Yan H, Xia S, Wang Z, et al
    A Rare Case of Refractory Duodenal Ulcer With Progressive Aggravation Despite Conventional Treatment.
    J Gastroenterol Hepatol. 2025 May 16. doi: 10.1111/jgh.17007.
    PubMed     Abstract available
    
    
    April 2025
55. BAIK M, Jeon J, Yoo J, Kim J, et al
    Effect of Potassium-Competitive Acid Blockers on Upper Gastrointestinal Bleeding in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study.
    J Gastroenterol Hepatol. 2025 Apr 27. doi: 10.1111/jgh.16989.
    PubMed     Abstract available
    
    
    
56. 
    Correction to "Endoscopic Versus Medical Management of Peptic Ulcers With Adherent Clots: Overcoming Hesitation Through Education".
    J Gastroenterol Hepatol. 2025 Apr 21. doi: 10.1111/jgh.16983.
    PubMed    
    
    
    
57. SI YT, Xiong XS, Zhang SK, Lai JX, et al
    Detection of Helicobacter pylori Infection and Antibiotic Resistance via String Test Coupled With qPCR Method: A Comparative Methodological Study.
    J Gastroenterol Hepatol. 2025 Apr 2. doi: 10.1111/jgh.16962.
    PubMed     Abstract available
    
    
    March 2025
58. WU J, Liao Y
    Balancing Benefits and Risks: The Role of Tranexamic Acid in Upper Gastrointestinal Bleeding.
    J Gastroenterol Hepatol. 2025 Mar 15. doi: 10.1111/jgh.16941.
    PubMed    
    
    
    February 2025
59. JEARTH V
    Management of Helicobacter pylori Infection: Do We Completely See Eye to Eye?
    J Gastroenterol Hepatol. 2025 Feb 6. doi: 10.1111/jgh.16904.
    PubMed    
    
    
    December 2024
60. OTANI K, Hang DV, Pittayanon R, Liu H, et al
    Asia-Pacific Survey on the Management of Helicobacter pylori Infection.
    J Gastroenterol Hepatol. 2024 Dec 26. doi: 10.1111/jgh.16862.
    PubMed     Abstract available
    
    
    
61. KAN SW, Tan YP, Tay MZ, Chi MJ, et al
    Tranexamic Acid With Acid Suppression Versus Acid Suppression Alone as Therapy for Upper Gastrointestinal Bleeding: A Meta-Analysis of Randomized Controlled Trials.
    J Gastroenterol Hepatol. 2024 Dec 4. doi: 10.1111/jgh.16842.
    PubMed     Abstract available
    
    
    
62. FUKASE H, Futagami S, Yamamoto T, Masaoka T, et al
    Investigation of the effects of a new transdermal formulation of systemic diclofenac on the upper gastrointestinal mucosa in patients with low back pain: A comparative study with oral diclofenac.
    J Gastroenterol Hepatol. 2024;39:2504-2510.
    PubMed     Abstract available
    
    
    November 2024
63. LIN A, Lin Z, Liu Y, Chen S, et al
    Ten-day versus 14-day vonoprazan-amoxicillin high-dose dual therapy for Helicobacter pylori eradication in China: A multicenter, open-label, randomized study.
    J Gastroenterol Hepatol. 2024 Nov 24. doi: 10.1111/jgh.16761.
    PubMed     Abstract available
    
    
    
64. KAZAKOS E, Kountouras J
    Helicobacter pylori Infection and Cholelithiasis.
    J Gastroenterol Hepatol. 2024 Nov 18. doi: 10.1111/jgh.16820.
    PubMed    
    
    
    
65. JUNG YS, Jung BW, Park CH
    Comparative efficacy of Helicobacter pylori eradication therapy between tegoprazan-based concomitant and bismuth quadruple therapies: A real-world evidence.
    J Gastroenterol Hepatol. 2024 Nov 18. doi: 10.1111/jgh.16798.
    PubMed     Abstract available
    
    
    October 2024
66. TAN JT, Cheung CL, Cheung KS
    Relationship between Helicobacter pylori infection, osteoporosis, and fracture.
    J Gastroenterol Hepatol. 2024;39:2006-2017.
    PubMed     Abstract available
    
    
    September 2024
67. HO CT, Tan EH, Lee PC, Su CW, et al
    Reply to "Association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy: concerns to be addressed".
    J Gastroenterol Hepatol. 2024 Sep 19. doi: 10.1111/jgh.16754.
    PubMed    
    
    
    
68. TANG WZ, Li JZ, Liu TH
    Evaluating vonoprazan bismuth-containing triple therapy versus quadruple therapy for Helicobacter pylori.
    J Gastroenterol Hepatol. 2024 Sep 18. doi: 10.1111/jgh.16753.
    PubMed    
    
    
    August 2024
69. JUNG BW, Park CH, Jung YS
    Efficacy and safety of tegoprazan- and rabeprazole-based concomitant therapies for Helicobacter pylori infection: Real-world evidence.
    J Gastroenterol Hepatol. 2024 Aug 26. doi: 10.1111/jgh.16719.
    PubMed     Abstract available
    
    
    
70. PAVONI M, Fiorini G, Zullo A, Saracino IM, et al
    Effectiveness of high-dose esomeprazole or pantoprazole 10-day sequential therapy empirically prescribed in Helicobacter pylori-infected naive patients: a retrospective study.
    J Gastroenterol Hepatol. 2024 Aug 26. doi: 10.1111/jgh.16731.
    PubMed     Abstract available
    
    
    
71. ISHIBASHI F, Suzuki S, Kobayashi K, Tanaka R, et al
    Cost-effective endoscopic screening for gastric cancer in a cohort with low Helicobacter pylori prevalence.
    J Gastroenterol Hepatol. 2024 Aug 9. doi: 10.1111/jgh.16715.
    PubMed     Abstract available
    
    
    
72. LIU J, Yin M, Lv C, Wang W, et al
    Post-reflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance predict proton pump inhibitor response in patients with reflux hypersensitivity.
    J Gastroenterol Hepatol. 2024 Aug 8. doi: 10.1111/jgh.16718.
    PubMed     Abstract available
    
    
    
73. HAYASAKA J, Hoteya S, Takazawa Y, Kikuchi D, et al
    Antacids and reflux esophagitis as a risk factor for gastric neoplasm of fundic-gland type: A retrospective, matched case-control study.
    J Gastroenterol Hepatol. 2024;39:1580-1585.
    PubMed     Abstract available
    
    
    July 2024
74. BIAN J, Sang X
    Association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy: Concerns to be addressed.
    J Gastroenterol Hepatol. 2024 Jul 25. doi: 10.1111/jgh.16694.
    PubMed    
    
    
    
75. LIANG JW, Xiong S, Jia YG, Xiao D, et al
    Comparison of vonoprazan bismuth-containing triple therapy with quadruple therapy in Helicobacter pylori-infected treatment-naive patients: a prospective multicenter randomized controlled trial.
    J Gastroenterol Hepatol. 2024 Jul 16. doi: 10.1111/jgh.16679.
    PubMed     Abstract available
    
    
    June 2024
76. ALLO G, Nierhoff D, Kasper P
    Endoscopic versus medical management of peptic ulcers with adherent clots: Overcoming hesitation through education.
    J Gastroenterol Hepatol. 2024 Jun 18. doi: 10.1111/jgh.16665.
    PubMed    
    
    
    
77. HO CT, Fu CC, Tan EC, Kao WY, et al
    The association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy.
    J Gastroenterol Hepatol. 2024 Jun 12. doi: 10.1111/jgh.16640.
    PubMed     Abstract available
    
    
    
78. WEI MH, Chen CC, Lee HC, Lee YC, et al
    Prevalence of functional esophageal disorders and associated clinical characteristics in patients with proton-pump-inhibitor-unresponsive reflux symptoms.
    J Gastroenterol Hepatol. 2024 Jun 11. doi: 10.1111/jgh.16654.
    PubMed     Abstract available
    
    
    May 2024
79. TASSONE D, Kazi S, Lee T, Gilmore R, et al
    Systematic review and meta-analysis of endoscopic versus medical management of peptic ulcers with adherent clots.
    J Gastroenterol Hepatol. 2024 May 31. doi: 10.1111/jgh.16611.
    PubMed     Abstract available
    
    
    
80. SCHUBERT JP, Tay A, Lee KHC, Leong LEX, et al
    Genomic analysis of Helicobacter pylori in Australia: Antimicrobial resistance, phylogenetic patterns, and virulence factors.
    J Gastroenterol Hepatol. 2024 May 29. doi: 10.1111/jgh.16636.
    PubMed     Abstract available
    
    
    
81. SONODA M, Matsumura T, Dao HV, Shiko Y, et al
    A prediction model of abnormal acid reflux in gastroesophageal reflux disease.
    J Gastroenterol Hepatol. 2024 May 15. doi: 10.1111/jgh.16602.
    PubMed     Abstract available
    
    
    
82. KOUNTOURAS J, Zavos C, Vardaka E, Kyrailidi F, et al
    Helicobacter pylori and metabolic syndrome-related adipokines in nonalcoholic fatty liver disease pathophysiology.
    J Gastroenterol Hepatol. 2024 May 9. doi: 10.1111/jgh.16621.
    PubMed    
    
    
    
83. LOOSEN SH, Killer A, Luedde T, Roderburg C, et al
    Helicobacter pylori infection associated with an increased incidence of cholelithiasis: A retrospective real-world cohort study of 50 832 patients.
    J Gastroenterol Hepatol. 2024 May 7. doi: 10.1111/jgh.16597.
    PubMed     Abstract available
    
    
    
84. CHEUNG KS, Yan VKC, Ye X, Hung IFN, et al
    Proton pump inhibitors associated with severe COVID-19 among two-dose but not three-dose vaccine recipients.
    J Gastroenterol Hepatol. 2024 May 5. doi: 10.1111/jgh.16601.
    PubMed     Abstract available
    
    
    
85. ZHAO X, Ciren Y, Wu D
    Gastrointestinal: A rare intra-abdominal hydatid cyst manifesting as an acute massive upper gastrointestinal bleeding.
    J Gastroenterol Hepatol. 2024 May 2. doi: 10.1111/jgh.16579.
    PubMed    
    
    
    February 2024
86. SOGABE M, Okahisa T, Kagawa M, Sei M, et al
    Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.
    J Gastroenterol Hepatol. 2024 Feb 29. doi: 10.1111/jgh.16530.
    PubMed     Abstract available
    
    
    
87. YAMAOKA Y
    Revolution of Helicobacter pylori treatment.
    J Gastroenterol Hepatol. 2024 Feb 27. doi: 10.1111/jgh.16526.
    PubMed     Abstract available
    
    
    
88. KIM NH, Chang Y, Ryu S, Sohn CI, et al
    Impact of metabolic unhealthiness and its changes on the risk of erosive esophagitis: a cohort study.
    J Gastroenterol Hepatol. 2024 Feb 21. doi: 10.1111/jgh.16519.
    PubMed     Abstract available
    
    
    
89. SIMADIBRATA DM, Lesmana E, Fass R
    Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
    J Gastroenterol Hepatol. 2024 Feb 14. doi: 10.1111/jgh.16486.
    PubMed     Abstract available
    
    
    
90. AYAR MS, Baydin A, Ustaoglu M, Caliskan F, et al
    Inferior vena cava collapsibility index and stroke volume as predictors of blood transfusion in upper gastrointestinal bleeding in the emergency department.
    J Gastroenterol Hepatol. 2024 Feb 9. doi: 10.1111/jgh.16500.
    PubMed     Abstract available
    
    
    January 2024
91. SIMADIBRATA DM, Lesmana E, Fass R
    A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    J Gastroenterol Hepatol. 2024 Jan 23. doi: 10.1111/jgh.16475.
    PubMed     Abstract available
    
    
    
92. ZHUANG Q, Liao A, He Q, Liu C, et al
    The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study.
    J Gastroenterol Hepatol. 2024 Jan 22. doi: 10.1111/jgh.16471.
    PubMed     Abstract available
    
    
    
93. MUFTAH M, Hartnett DA, Flanagan R, Redd WD, et al
    Allergic phenotype identified on allergen testing is associated with proton pump inhibitor nonresponse in eosinophilic esophagitis.
    J Gastroenterol Hepatol. 2024 Jan 7. doi: 10.1111/jgh.16469.
    PubMed     Abstract available
    
    
    November 2023
94. SUN Y, Zhang A, Zuo M, Chen J, et al
    A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database.
    J Gastroenterol Hepatol. 2023 Nov 14. doi: 10.1111/jgh.16411.
    PubMed     Abstract available
    
    
    
95. BAILEY ME, Borges LF, Goldberg HJ, Hathorn KE, et al
    Abnormal bolus reflux on impedance-pH testing independently predicts 3-year pulmonary outcome and mortality in pulmonary fibrosis.
    J Gastroenterol Hepatol. 2023;38:1998-2005.
    PubMed     Abstract available
    
    
    
96. NABI Z, Ramchandani M, Basha J, Inavolu P, et al
    Per-oral endoscopic myotomy in cases with prior Heller's myotomy: Outcomes at a median follow-up of 5 years.
    J Gastroenterol Hepatol. 2023;38:2035-2039.
    PubMed     Abstract available
    
    
    October 2023
97. SHIMAMURA Y, Inoue H, Tanabe M, Ushikubo K, et al
    Clinical outcomes of anti-reflux mucosal ablation for gastroesophageal reflux disease: An international bi-institutional study.
    J Gastroenterol Hepatol. 2023 Oct 3. doi: 10.1111/jgh.16370.
    PubMed     Abstract available
    
    
    September 2023
98. ZENG SY, Wang J, Liu J, Lin MJ, et al
    Efficacy and safety of a 14-day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study.
    J Gastroenterol Hepatol. 2023 Sep 13. doi: 10.1111/jgh.16348.
    PubMed     Abstract available
    
    
    August 2023
99. YU Y, Liao Z, Jiang X, Pan J, et al
    The use of magnet-controlled capsule endoscopy as the initial diagnostic tool in patients with acute upper gastrointestinal bleeding.
    J Gastroenterol Hepatol. 2023 Aug 3. doi: 10.1111/jgh.16310.
    PubMed     Abstract available
    
    
    
100. OHKI D, Tsuji Y, Kuroda R, Ushiku T, et al
     Gastrointestinal: A case of significant esophageal ulceration due to oral iron pill therapy.
     J Gastroenterol Hepatol. 2023;38:1241.
     PubMed    
     
     
     July 2023
101. YOU N, Chen Y, Yan X, Gu B, et al
     Persistent Helicobacter pylori infection leads to elevated fasting plasma glucose level: A retrospective cohort study based on a nondiabetes Chinese population.
     J Gastroenterol Hepatol. 2023 Jul 4. doi: 10.1111/jgh.16275.
     PubMed     Abstract available
     
     
     June 2023
102. EL HAGE CHEHADE N, Fu Y, Ghoneim S, Shah S, et al
     Association between obstructive sleep apnea and gastroesophageal reflux disease: A systematic review and meta-analysis.
     J Gastroenterol Hepatol. 2023 Jun 10. doi: 10.1111/jgh.16245.
     PubMed     Abstract available
     
     
     April 2023
103. GULIYARA MA, Ermerak G, Levy M, Koo JH, et al
     Frailty predicts mortality in patients with Upper Gastrointestinal bleed: A prospective cohort study.
     J Gastroenterol Hepatol. 2023 Apr 1. doi: 10.1111/jgh.16188.
     PubMed     Abstract available
     
     
     March 2023
104. CHANG A, Rugivarodum M, Pungpipattrakul N, Akarapatima K, et al
     Role of Oral Iron Supplementation for Anemia Secondary to Acute Nonvariceal Upper Gastrointestinal Bleeding: A Randomized Controlled Trial.
     J Gastroenterol Hepatol. 2023 Mar 30. doi: 10.1111/jgh.16185.
     PubMed     Abstract available
     
     
     
105. SARUTA Y, Watanabe K, Tsuji T, Takahashi Y, et al
     Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors.
     J Gastroenterol Hepatol. 2023 Mar 7. doi: 10.1111/jgh.16169.
     PubMed     Abstract available
     
     
     
106. MATSUURA N, Kato M, Irino T, Hirata K, et al
     Gastrointestinal: Ten-millimeter advanced duodenal cancer with a gastric phenotype.
     J Gastroenterol Hepatol. 2023;38:347.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Peptic Ulcer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum